RC220 advances: Race Oncology hits key dosing milestone
Last updated: 09:45 02 May 2025 AEST, First published: 08:45 02 May 2025 AEST
Race Oncology Ltd managing director Daniel Tillett talked with Proactive about the company's recent milestone in dosing the first patient in its Phase 1 clinical trial of RC220 for advanced solid tumours.
Tillett explained the years-long development effort behind RC220, which required reformulating a drug that had previously shown promise but could not be administered safely.
He highlighted the elimination of phlebitis, a prior barrier to clinical use, as a critical breakthrough in the new formulation. The trial also investigates RC220's potential dual function: treating cancer and protecting the heart. Tillett discussed preclinical evidence suggesting cardioprotective effects, especially when RC220 is used alongside doxorubicin, a commonly used but cardiotoxic chemotherapy drug.
The Phase 1 trial is being conducted across multiple sites in Australia, with international expansion into Hong Kong and South Korea expected during the year. Up to 33 patients will participate in the first stage of dose finding, followed by up to 20 patients in the dose expansion phase.
Tillett noted that RC220 has already been used in over 50 historical trials, supporting its de-risked profile as it moves forward in this new application.
? For more company updates and expert interviews, visit Proactive's YouTube channel. Don’t forget to like the video, subscribe, and enable notifications for future content.
#RaceOncology #RC220 #CancerTreatment #ClinicalTrials #OncologyNews #BiotechUpdates #Cardioprotection #Doxorubicin #PharmaNews #ProactiveInvestors
